Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.51 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30067792 | 1.00 | TP53 (0.57) | TP53PGRCDYL2CDYLLMNA | |
| SCHEMBL947797 | 0.84 | NQO2 (0.58) | TP53PGRCDYL2CDYLLMNA | |
| SCHEMBL14484996 | 0.84 | CDYL2 (0.58) | TP53PGRCDYL2CDYLLMNA | |
| SCHEMBL7382582 | 0.83 | CDYL2 (0.57) | TP53PGRCDYL2CDYLLMNA | |
| SCHEMBL7385586 | 0.83 | CDYL2 (0.60) | TP53PGRCDYL2CDYLLMNA | |
| SCHEMBL24019919 | 0.80 | PGR (0.57) | TP53PGRLMNAMAPTALDH1A1 | |
| SCHEMBL2988866 | 0.80 | PGR (0.57) | TP53PGRLMNAMAPTALDH1A1 | |
| SCHEMBL15730582 | 0.80 | MAOA (0.51) | TP53PGRCDYL2CDYLMAOA | |
| SCHEMBL2986303 | 0.79 | PGR (0.72) | TP53PGRCDYL2CDYLLMNA | |
| SCHEMBL2320598 | 0.79 | PGR (0.56) | TP53PGRCDYL2CDYLLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | TP53 4333/4885PGR 1804/4885CDYL2 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.